Claims for Patent: 6,440,738

Summary for Patent: 6,440,738

Title:	Antisense modulation of casein kinase 2-beta expression
Abstract:	Antisense compounds, compositions and methods are provided for modulating the expression of Casein kinase 2-beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Casein kinase 2-beta. Methods of using these compounds for modulation of Casein kinase 2-beta expression and for treatment of diseases associated with expression of Casein kinase 2-beta are provided.
Inventor(s):	Wyatt; Jacqueline (Encinitas, CA)
Assignee:	ISIS Pharmaceuticals, Inc. (Carlsbad, CA)
Application Number:	09/780,175
Patent Claims:	1. A compound 8 to 50 nucleobases in length targeted to nucleobases 1039 through 1394 of a 5'-untranslated region, nucleobases 1622 through 1641 or nucleobases 3341 through 3360 of a coding region, or nucleobases 1875 through 3270 of an intron region of a nucleic acid molecule encoding human Casein kinase 2-beta of SEQ ID NO: 17, to nucleobases 124 through 287 of a 5'-untranslated region, nucleobases 1035 through 1121 of a 3'-untranslated region, or nucleobases 348 through 428, nucleobases 423 through 462, nucleobases 470 through 523, nucleobases 541 through 568, nucleobases 578 through 603, nucleobases 629 through 648, nucleobases 661 through 696, nucleobases 711 through 730, nucleobases 761 through 851, nucleobases 860 through 879, nucleobases 886 through 905, or nucleobases 930 through 996 of a coding region of a nucleic acid molecule encoding human Casein kinase 2-beta of SEQ ID NO: 3, to nucleobases 1054 through 1103 of a 3'-untranslated region, or nucleobases 345 through 408, nucleobases 415 through 481, nucleobases 490 through 509, nucleobases 576 through 595, nucleobases 606 through 707, nucleobases 780 through 799, nucleobases 804 through 843, or nucleobases 880 through 988 of a nucleic acid molecule encoding murine Casein kinase 2-beta of SEQ ID NO: 10, or to nucleobases 1734 through 1964 of a 5'-untranslated region, nucleobases 2290 though 2729 or nucleobases 3157 through 6184 of an intron region or nucleobases 2821 through 2840 of a coding region of a nucleic acid molecule encoding murine Casein kinase 2-beta of SEQ ID NO:96, wherein said antisense compound specifically hybridizes with one of said regions and inhibits the expression of human or murine Casein kinase 2-beta. 2. The compound of cliam 1 which is an antisense oligonucleotide. 3. A compound up to 50 nucleobases in length comprising at least an 8-nucleobase portion of SEQ ID NO: 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 93, 94, 95, 92, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 114, 115, 116, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153 or 154 which inhibits the expression of human or murine Casein kinase 2-beta. 4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 5. The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage. 6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 7. The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 8. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 9. The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine. 10. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 11. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 12. The composition of claim 11 further comprising a colloidal dispersion system. 13. The composition of claim 11 wherein the compound is an antisense oligonucleotide. 14. A method of inhibiting the expression of human or murine Casein kinase 2-beta in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of human or murine Casein kinase 2-beta is inhibited. 15. The compound of claim 3 which is an antisense oligonucleotide. 16. The compound of claim 15, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 17. The compound of claim 16, wherein the modified internucleoside linkage is a phosphorothioate linkage. 18. The compound of claim 15, wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 19. The compound of claim 18 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 20. The compound of claim 15, wherein the antisense oligonucleotide comprises at least one modified nucleobase. 21. The compound of claim 20 wherein the modified nucleobase is a 5-methylcytosine. 22. The compound of claim 15 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 23. A method of inhibiting the expression of human or murine Casein kinase 2-beta in human cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 3 so that expression of human or murine Casein kinase 2-beta is inhibited. 24. A composition comprising the compound of claim 3 and a pharmaceutically acceptable carrier or diluent. 25. The composition of claim 24 further comprising a colloidal dispersion system. 26. The composition of claim 24 wherein the compound is an antisense oligonucleotide.

Details for Patent 6,440,738

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26